HIV

The FDA approved Triumeq (abacavir, dolutegravir, and lamivudine) tablets for the treatment of HIV-1 infection in patients without the HLA-B*5701 allele.

High cost of new drugs make treating even the sickest inmates impractical.

Gilead Sciences is seeking FDA approval for emtricitabine/tenofovir alafenamide.

Lack of adherence remains a major source of health care costs among HIV patients.

Accelerated aging of DNA can lead to diseases such as cancer and osteoporosis.

Vast majority of children with HIV experience recovery of immune system following therapy.

Combination fast-tracked for approval to treat chronic HCV GT1 infection in end-stage renal disease patients on hemodialysis.

While health care providers generally favor pre-exposure prophylaxis (PrEP) for patients at high risk of acquiring human immunodeficiency virus (HIV), many hesitate to actually prescribe it.

HIV antiviral therapy can prevent infection from establishing in at-risk individuals.

HIV patients need to have undetectable viral load to undergo procedure.

A New York pharmacist was sentenced to 3 years in prison and will have to pay more than $7 million in restitution for his scheme to defraud Medicare, Medicaid, and an AIDS program.

Moderate to intense exercise carries wide range of benefits.

Recent spike in HIV cases linked to intravenous drug use.

Risk of HIV transmission is higher in the acute phase than the chronic one.

The pharmacist's role as a disease educator is moving to the forefront.

Commonly cited estimates on how easily newly infected patients transmit HIV may be vastly overstated.

Nearly half of all infected patients not receiving medical care.

Study finds HIV-1 viral loads decreased following treatment with Valtrex.

A drug typically used to treat herpes may reduce HIV-1 levels, even in those who don't have herpes.

More than 90% of HIV transmissions originate from undiagnosed and untreated individuals. On the other hand, those retained in medical care who have achieved viral suppression are 94% less likely to transmit HIV.

Scientists seek to create powerful defense system that will both attack the virus and prevent infection.

Study evaluates how antiretroviral therapy effects gut microbiota.

Post-exposure prophylaxis has proven to be effective.

New drugs help prevent needless HCV-related deaths.

The new Gardasil vaccine protects against 9 different strains of the virus.

Interferon-free, all-oral drug regimens result in high rates of sustained virologic response for patients co-infected with hepatitis C virus and HIV.

Mortality rates also affected by age and poor nutrition.

Study finds that 61 to 82% of patients treated with experimental drug achieved undetectable viral replication levels.

Preventing exposures to blood and body fluids is critical to preventing occupationally acquired HIV.

Experimental drug found to be so powerful and universally effective, it may lead to an unconventional vaccine.